[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"injection-drug-use\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:injection-drug-use":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,74,105],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100637702","feasibility-of-internet-based-hiv-prevention-research-100637702",false,"NCT07625917","Feasibility of Internet-based HIV Prevention Research","Inclusion Criteria:\n\n* 18 years or older\n* US residency\n* English or Spanish fluency\n* injection drug use (self-report, past 30 days)\n* basic reading comprehension\n\nExclusion Criteria:\n\n* HIV status known to be positive","ALL","18 Years",{"count":18,"type":19},500,"ESTIMATED","INTERVENTIONAL",[22],"NA","The study will use social media to recruit a diverse sample of people who self-report injecting drugs, assessing the feasibility of online assessments and participants' ability to perform at-home self-administered HIV testing. Participants will complete online questionnaires at baseline and will be mailed HIV testing kits that they will self-administer and mail to a central laboratory. Investigators will track completion of questionnaires and whether at-home self-administered HIV tests were completed and sent to the laboratory.",[25,26],"HIV Prevention","Injection Drug Use",[28],"HIV testing","RECRUITING","2026-05-29",{"date":32,"type":33},"2026-06-04","ACTUAL",{"date":35,"type":33},"2025-08-01",{"date":37,"type":19},"2028-05-29",{"name":39,"class":40},"Montefiore Medical Center","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":20,"phases":53,"briefSummary":55,"conditions":56,"keywords":60,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":41},"100579818","phase-4-assessment-of-metformin-for-restoration-of-immune-homeostasis-in-hiv-and-hiv--individuals-with-a-history-of-injection-drug-use-100579818","NCT06829238","Assessment of Metformin for Restoration of Immune Homeostasis in HIV+ and HIV- Individuals With a History of Injection Drug Use","Assessment of Metformin for Restoration of Immune Homeostasis in HIV+ and HIV- Individuals With a History of Injection Drug Use (MET-IH)","(MET-IH)","Inclusion Criteria:\n\n* Provision of signed and dated informed consent.\n* Stated willingness to comply with all study procedures and availability for the study duration.\n* Aged 18 to 64 years old.\n* Weight of at least 110 lbs.\n* Body Mass Index (BMI) of 18.5-40. Enrollment of individuals with BMI \\>40, deemed in good health, may be considered with approval.\n* Willingness to receive Jynneos (MPOX) and Capvaxvie vaccines.\n* Ability to take oral medication and willingness to adhere to the metformin treatment regimen.\n* History of injection opioid, amphetamine, and\u002For cocaine use within the past 10 years (self-report).\n* Use of non-prescription opioid, amphetamine, and\u002For cocaine within the past 30 days (self-report).\n* Clinically confirmed urine drug screen for opioid, amphetamine, and\u002For cocaine within the past 30 days.\n* Serum CRP \\> 3 mg\u002FdL.\n* Glucose level between 70-180 mg\u002FdL (non-fasting).\n* Hemoglobin A1c (HbA1c) of 5.0-6.4%.\n* CD4 count \\> 200 cells\u002Fml.\n* If HIV-positive, HIV viral load \\\u003C 200 copies\u002Fml.\n* If HIV-positive, on anti-retroviral therapy (ART) for \\>12 months.\n\nExclusion Criteria:\n\n* Inability to give informed consent.\n* Refusal or inability to have blood drawn.\n* Bleeding disorder diagnosed by a doctor (e.g., factor deficiency, coagulopathy, platelet disorder requiring precautions).\n* Pregnant or nursing individuals.\n* Diabetes mellitus.\n* History of severe renal impairment or eGFR \\\u003C60 mL\u002Fmin\u002F1.73m².\n* Creatinine clearance \\\u003C60 mL\u002Fmin.\n* History of liver disease.\n* ALT\u002FAST \\> 3× the upper limit of normal.\n* Total bilirubin \\>1.4 mg\u002FdL.\n* Albumin \\\u003C3.5 g\u002FdL.\n* Prothrombin \\>1.5× the upper limit of normal.\n* AUDIT-C score ≥8.\n* Hemoglobin \\\u003C9.0 g\u002FL.\n* Absolute neutrophil count \\\u003C1,000\u002FmL.\n* Platelet count \\\u003C100,000\u002FmL.\n* History of acute or chronic metabolic acidosis.\n* Serum bicarbonate \\\u003C22 mEq\u002FL.\n* Anion gap \\>10 mEq\u002FL.\n* Serum lactate \\>2.2 mmol\u002FL.\n* Serum vitamin B12 \\\u003C250 pg\u002FmL.\n* History of chronic diarrhea.\n* Current use of metformin or other diabetes medications.\n* History of myocardial infarction, endocarditis, stroke, heart failure, chronic obstructive pulmonary disease, or sepsis.\n* Use of medications such as furosemide, nifedipine, ranolazine, vandetanib, or cimetidine (current or within the past 30 days).\n* Active hepatitis B infection.\n* Hepatitis C infection within 6 months of study entry; individuals with prior hepatitis C must be at least 6 months post-treatment with direct-acting antivirals.\n* Previous receipt of Jynneos or pneumococcal vaccine within the past two years (self-report).\n* Severe allergic reaction to metformin, Jynneos, or Capvaxvie (self-report). Blood donations exceeding 450 mL in the 8 weeks prior to enrollment, accounting for study-related blood draws.\n* Any medical, psychiatric, social condition, or responsibility that, in the investigator's judgment, could interfere with study procedures.","64 Years",{"count":52,"type":19},100,[54],"PHASE4","This randomized clinical trial (RCT) evaluates whether metformin can reduce systemic inflammation and improve immune function in individuals with a history of injection drug use, with or without HIV. Participants will receive metformin or placebo and undergo immune system assessments, including vaccine response evaluations.",[57,58,26,59],"Systemic Inflammation","Immune Dysregulation","HIV",[61,62,63,64],"Metformin","Immune restoration","Vaccine response","People who inject drugs (PWID)","2026-04-17",{"date":67,"type":33},"2026-04-22",{"date":69,"type":33},"2025-04-07",{"date":71,"type":19},"2029-11-30",{"name":73,"class":40},"University of Alabama at Birmingham",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":20,"phases":83,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":104},"100608267","phase-4-long-acting-cabotegravir-injectable-pre-exposure-prophylaxis-for-people-who-inject-drugs-100608267","NCT07199335","Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject Drugs","A Multi-Center Assessment of an Intervention to Provide Long-Acting Cabotegravir Injectable Pre-Exposure Prophylaxis to People Who Inject Drugs","ASCEND","Inclusion Criteria:\n\n* HIV Ab\u002FAg test (lab-based or rapid) negative at time of enrollment\n* ≥18 years old\n* Able to provide informed consent\n* Have injected non-prescribed drugs within the past 6 months\n* No prior history of receiving cabotegravir (Note: prior or active use of non-CAB PrEP (\\[FTC\u002FTDF or FTC\u002FTAF\\]) at screening is allowed, but participant will need to indicate that they prefer to switch to injectable PrEP).\n* PrEP provider deems cabotegravir use to be appropriate per the applicable prescribing information prior to enrollment in the study.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding people. Should a participant become pregnant, the treating physician will discuss with the participant whether to continue study medication, taking into consideration the risks and benefits of continuing cabotegravir compared with the risk of switching to an alternative recommended PrEP regimen.\n* Has not had vaginal or anal sex in the past 6 months\n* HIV indeterminate or positive test result during screening and prior to initiation of CAB PrEP\n* Already diagnosed with HIV\n* Taking any of the following medications: Carbamazepine, Rifampin, Oxcarbazepine, Rifapentine, Phenobarbital, Phenytoin",{"count":52,"type":19},[54],"The goal of this study is to determine the feasibility and impact of delivering long-acting injectable cabotegravir HIV pre-exposure prophylaxis and suite of support services to adults who inject non-prescription drugs who are risk for HIV through known sexual risk.",[59,86,26],"Substance Use Disorder (SUD)",[59,88,89,90,91,92,93,94],"Substance use","pre-exposure prophylaxis","cabotegravir","long-acting cabotegravir","PrEP","implementation science","PrEP navigator","2026-03-17",{"date":97,"type":33},"2026-03-19",{"date":99,"type":33},"2026-02-24",{"date":101,"type":19},"2028-12",{"name":103,"class":40},"Massachusetts General Hospital",2,{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":20,"phases":115,"briefSummary":116,"conditions":117,"keywords":121,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":41},"100589366","phase-4-implementing-low-barrier-hcv-treatment-in-a-jail-setting-100589366","NCT06953479","Implementing Low-Barrier HCV Treatment in a Jail Setting","MINMON-J: An Effectiveness Implementation Pilot Study Evaluating a Low-barrier Hepatitis C Treatment Model in a Jail Setting","MINMON-J","Inclusion Criteria:\n\n* Incarcerated individual at RIDOC\n* Age ≥ 18 years\n* Awaiting trial (i.e., not sentenced)\n* English speaking\n* Diagnosis of active HCV (HCV RNA \\>1000 IU\u002FmL within 90 days prior to study entry)\n* Treatment-naïve for current HCV infection\n* No cirrhosis (FIB-4 Score \\\u003C3.25 within 90 days prior to study entry)\n* Self-report of injection drug use\n* Ability and willingness to be contacted after jail release\n* Verbal commitment to continue medication after discharge\n* Desire to receive Sofosbuvir\u002FVelpatasvir (Epclusa)\n\nExclusion Criteria:\n\n* Cirrhosis (FIB-4 Score \\>3.25 within 90 days prior to study entry and\u002For clinical signs of cirrhosis)\n* Positive for Hepatitis B surface antigen\n* Actively pregnant or breastfeeding\n* Known allergy\u002Fsensitivity to study drug components\n* Acute or serious illness requiring hospitalization at enrollment\n* Documented severe persistent mental illness (SPMI) by RIDOC\n* Any clinical history of hepatic decompensation (e.g., ascites, SBP, HE, HRS, variceal bleeding)\n* HIV-positive with active or acute AIDS-defining opportunistic infection within 90 days",{"count":114,"type":19},40,[54],"The goal of this clinical trial is to learn whether a low-barrier treatment program can help people with hepatitis C virus (HCV) who are in jail start and complete treatment more easily. This study focuses on adults at the Rhode Island Department of Corrections who have active HCV and are awaiting trial.\n\nThe study asks:\n\n* Can a simplified, low-barrier HCV treatment program work in a jail setting?\n* Do participants finish treatment and get cured using this approach?\n\nAll participants will receive a 12-week course of the HCV medication sofosbuvir\u002Fvelpatasvir (Epclusa). If they are released before completing treatment, they will take the remaining doses with them. Community Health Workers (CHWs) will help support participants after release, including reminding them to take medications and helping them get follow-up lab work.\n\nResearchers will measure:\n\n* Whether participants are cured of HCV\n* Whether the treatment approach is easy to use (feasible), acceptable, and followed correctly (fidelity)\n* Whether the program could be used in other jails or expanded in the future\n\nThis study may help bring HCV treatment to more people in jail, reduce community spread of the virus, and support national goals to eliminate HCV.",[118,119,26,120],"HEPATITIS C (HCV)","Incarceration","Implementation Science",[122,123,124,125,126,127,93],"hepatitis c","incarceration","jail","injection drug use","minimal monitoring","MINMON","2026-02-26",{"date":130,"type":33},"2026-02-27",{"date":132,"type":33},"2025-06-11",{"date":134,"type":19},"2027-08",{"name":136,"class":40},"Lifespan"]